IRVINE, CA, / ACCESSWIRE / August 29, 2019 / PRO-DEX, INC. PDEX today announced financial results for its fiscal 2019 fourth quarter and full-year ended June 30, 2019.
Quarter Ended June 30, 2019
Net sales for the three months ended June 30, 2019 increased $756,000, or 12%, to $7.0 million from $6.2 million for the three months ended June 30, 2018, due primarily to increased medical device sales and repair revenue generated from our largest customer of a product used in orthopedic surgical applications. Gross profit for the three months ended June 30, 2019 increased $153,000, or 6%, to $2.5 million from $2.4 million for the same period in 2018. The increase in gross margin is due to better absorption of our fixed costs due to higher sales volumes, as well as manufacturing efficiencies derived this fiscal year from higher volumes and continued investment in new machinery.
Operating expenses (which include selling, general and administrative, and research and development expenses) for the quarter ended June 30, 2019 decreased 27% to $1.4 million from $1.9 million in the prior year's corresponding quarter, due primarily to the prior year impairment of our entire $800,000 investment in Monogram Orthopaedics Inc. ("Monogram") offset by increased expenditures of $61,000 in selling expenses and $97,000 in research and development costs to support our continued efforts to further grow our business, as well as an increase of $148,000 in general and administrative expenses due to increased bonus accruals.
Net income for the quarter ended June 30, 2019 increased by $720,000, to $888,000, or $0.21 per diluted share, compared to $168,000, or $0.04 per diluted share, in the corresponding quarter in 2018.
Year Ended June 30, 2019
Net sales for the fiscal year ended June 30, 2019 increased $4.7 million, or 21%, to $27.2 million from $22.5 million for the fiscal year ended June 30, 2018, due primarily to increases in medical device revenues. Specifically, our largest customer accounted for an increase of $4.6 million in revenue during fiscal 2019.
Gross profit for the fiscal year ended June 30, 2019 increased $1.8 million, or 23%, to $9.8 million compared to $7.9 million for fiscal 2018, due to increased revenues and manufacturing efficiencies.
Operating expenses (which include selling, general and administrative, and research and development expenses) for the fiscal year ended June 30, 2019 decreased 14% to $4.8 million from $5.6 million in the prior fiscal year, due in part to the prior year impairment charges related to our Monogram investment as well as our Fineline Molds division, which we sold in May 2018.
Net income for the fiscal year ended June 30, 2019 was $4.2 million, or $0.97 per diluted share, compared to $1.6 million, or $0.37 per diluted share, for fiscal 2018.
Although the Company has released its earnings prior to the filing of its annual Form 10-K with the Securities and Exchange Commission, we are able to do this because we are a non-accelerated filer and as a result have more time to do so at fiscal year-end. During our quarterly reporting periods we anticipate that our earnings releases will continue to be released at the same time as our Form 10-Q's are filed with the Securities and Exchange Commission. We anticipate filing our Form 10-K with the Securities and Exchange Commission on September 12, 2019.
CEO Comments
Richard L. ("Rick") Van Kirk, the Company's President and Chief Executive Officer, commented, "We are pleased with our fiscal 2019 results, especially our fourth quarter sales which is a record for the Company. We will focus our fiscal 2020 efforts on additional organic sales growth and continue our efforts to pursue our product roadmap."
About Pro-Dex, Inc.:
Pro-Dex, Inc. specializes in the design, development, and manufacture of autoclavable, battery-powered, and electric multi-function surgical drivers and shavers used primarily in the orthopedic, spine, and maxocranial facial markets. We have patented adoptive torque-limiting software and proprietary sealing solutions which appeal to our customers, primarily medical device distributors. Pro-Dex also sells rotary air motors. Pro-Dex's products are found in hospitals and medical engineering labs around the world. For more information, visit the Company's website at www.pro-dex.com.
Statements herein concerning the Company's plans, growth and strategies may include "forward-looking statements" within the context of the federal securities laws. Statements regarding the Company's future events, developments and future performance, as well as management's expectations, beliefs, plans, estimates, or projections relating to the future are forward-looking statements within the meaning of these laws. The Company's actual results may differ materially from those suggested as a result of various factors. Interested parties should refer to the disclosure concerning the operational and business concerns of the Company set forth in the Company's filings with the Securities and Exchange Commission.
(tables follow)
PRO-DEX, INC.
BALANCE SHEETS
In thousands, except share data)
| June 30, | ||||||||
| 2019 | 2018 | |||||||
ASSETS | ||||||||
Current assets: | ||||||||
Cash and cash equivalents | $ | 7,742 | $ | 5,188 | ||||
Investments | 2,649 | 2,220 | ||||||
Accounts receivable, net of allowance for doubtful accounts of $0 and $14 at June 30, 2019 and 2018, respectively. | 4,100 | 2,955 | ||||||
Deferred costs | 430 | 32 | ||||||
Notes receivable | - | 1,176 | ||||||
Inventory | 6,239 | 4,393 | ||||||
Prepaid expenses and other current assets | 623 | 269 | ||||||
Total current assets | 21,783 | 16,233 | ||||||
Plant, equipment and leasehold improvements, net | 2,726 | 1,755 | ||||||
Intangibles, net | 129 | 140 | ||||||
Deferred income taxes, net | 260 | 1,678 | ||||||
Investments | 582 | - | ||||||
Notes receivable, net of current portion | - | 43 | ||||||
Other assets | 40 | 68 | ||||||
Total assets | $ | 25,520 | $ | 19,917 | ||||
LIABILITIES AND SHAREHOLDERS' EQUITY | ||||||||
Current liabilities: | ||||||||
Accounts payable | $ | 1,996 | $ | 1,083 | ||||
Accrued liabilities | 1,437 | 1,266 | ||||||
Deferred revenue | 215 | 31 | ||||||
Note payable and capital lease obligations | 622 | 35 | ||||||
Total current liabilities | 4,270 | 2,415 | ||||||
Non-current liabilities: | ||||||||
Deferred rent | 146 | 97 | ||||||
Income taxes payable | 162 | 123 | ||||||
Notes and capital lease payable, net of current portion | 3,934 | 6 | ||||||
Total non-current liabilities | 4,242 | 226 | ||||||
Total liabilities | 8,512 | 2,641 | ||||||
Commitments and Contingencies: | ||||||||
Shareholders' equity: | ||||||||
Common stock, no par value, 50,000,000 shares authorized; 4,039,491 and 4,331,089 shares issued and outstanding at June 30, 2019 and 2018, respectively | 15,815 | 19,835 | ||||||
Accumulated other comprehensive loss | (549 | ) | (153 | ) | ||||
Retained earnings (accumulated deficit) | 1,742 | (2,406 | ) | |||||
Total shareholders' equity | 17,008 | 17,276 | ||||||
Total liabilities and shareholders' equity | $ | 25,520 | $ | 19,917 | ||||
PRO-DEX, INC. AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF OPERATIONS
(In thousands, except per share data)
Three Months Ended June 30, (Unaudited) | Years Ended June 30, | |||||||||||||||
| 2019 | 2018 | 2019 | 2018 | |||||||||||||
Net sales | $ | 7,003 | $ | 6,247 | $ | 27,172 | $ | 22,465 | ||||||||
Cost of sales | 4,461 | 3,858 | 17,392 | 14,522 | ||||||||||||
Gross profit | 2,542 | 2,389 | 9,780 | 7,943 | ||||||||||||
Operating (income) expenses: Selling expenses | 162 | 101 | 415 | 358 | ||||||||||||
General and administrative expenses | 654 | 506 | 2,492 | 2,287 | ||||||||||||
Asset impairment charges | - | 800 | - | 1,029 | ||||||||||||
Gain from disposal of equipment | - | - | (7 | ) | (16 | ) | ||||||||||
Research and development costs | 545 | 448 | 1,882 | 1,893 | ||||||||||||
Total operating expenses | 1,361 | 1,855 | 4,782 | 5,551 | ||||||||||||
Operating profit | 1,181 | 534 | 4,998 | 2,392 | ||||||||||||
Interest expense | (65 | ) | (1 | ) | (220 | ) | (7 | ) | ||||||||
Other income | 10 | - | 45 | - | ||||||||||||
Gain in sale of investments | - | - | 356 | - | ||||||||||||
Interest and dividend income | 42 | 59 | 268 | 225 | ||||||||||||
Income before income taxes | 1,168 | 592 | 5,447 | 2,610 | ||||||||||||
Income tax expense | 280 | 424 | 1,299 | 989 | ||||||||||||
Net income | $ | 888 | $ | 168 | $ | 4,148 | $ | 1,621 | ||||||||
Basic & Diluted income per share: | ||||||||||||||||
Basic net income per share | $ | 0.22 | $ | 0.04 | $ | 0.99 | $ | 0.38 | ||||||||
Diluted net income per share | $ | 0.21 | $ | 0.04 | $ | 0.97 | $ | 0.37 | ||||||||
Weighted average shares outstanding: | ||||||||||||||||
Basic | 4,098,450 | 4,349,487 | 4,192,365 | 4,304,602 | ||||||||||||
Diluted | 4,204,365 | 4,389,268 | 4,298,332 | 4,344,765 | ||||||||||||
PRO-DEX, INC.
STATEMENTS OF CASH FLOWS
(In thousands)
| Years Ended June 30, | ||||||||
| 2019 | 2018 | |||||||
CASH FLOWS FROM OPERATING ACTIVITIES: | ||||||||
Net income | $ | 4,148 | $ | 1,621 | ||||
Adjustments to reconcile net income to net cash provided by operating activities: | ||||||||
Depreciation and amortization | 438 | 557 | ||||||
Gain on sale of investments | (356 | ) | - | |||||
Gain on sale or disposal of equipment | (7 | ) | (16 | ) | ||||
Amortization of loan fees | 7 | - | ||||||
Asset impairment charges | - | 1,029 | ||||||
Share-based compensation | 37 | 194 | ||||||
Deferred income taxes | 1,418 | 391 | ||||||
Bad debt expense (recovery) | (14 | ) | 14 | |||||
Changes in operating assets and liabilities: | ||||||||
Accounts receivable | (1,131 | ) | 569 | |||||
Deferred costs | (398 | ) | (19 | ) | ||||
Assets held for sale | - | 31 | ||||||
Inventory | (1,846 | ) | (1,309 | ) | ||||
Prepaid expenses and other assets | (326 | ) | (45 | ) | ||||
Accounts payable, accrued expenses and deferred rent | 1,133 | (57 | ) | |||||
Deferred revenue | 184 | 13 | ||||||
Income taxes payable | 39 | 123 | ||||||
Net cash provided by operating activities | 3,326 | 3,096 | ||||||
CASH FLOWS FROM INVESTING ACTIVITIES: | ||||||||
Purchases of equipment and leasehold improvements | (1,387 | ) | (923 | ) | ||||
Purchase of notes receivable | - | (350 | ) | |||||
Investment in Loan Participation | - | (1,150 | ) | |||||
Proceeds from dividend reclassified as return of principal | 23 | - | ||||||
Proceeds from sale of equipment | 7 | 30 | ||||||
Proceeds from collection of notes receivable | 1,219 | - | ||||||
Proceeds from sale of investments | 1,905 | - | ||||||
Increase in intangibles | (11 | ) | (11 | ) | ||||
Purchase of investments | (2,978 | ) | (1,711 | ) | ||||
Net cash used in investing activities | (1,222 | ) | (4,115 | ) | ||||
CASH FLOWS FROM FINANCING ACTIVITIES: | ||||||||
Principal payments on capital lease and note payable | (433 | ) | (78 | ) | ||||
Proceeds from shares issued under ATM | - | 2,262 | ||||||
Borrowing from Minnesota Bank & Trust, net of loan origination fees | 4,940 | - | ||||||
Repurchases of common stock | (3,984 | ) | (220 | ) | ||||
Payments of employee taxes on net issuance of common stock | (101 | ) | - | |||||
Proceeds from exercise of stock options and ESPP contributions | 28 | 38 | ||||||
Net cash provided by financing activities | 450 | 2,002 | ||||||
Net increase in cash and cash equivalents | 2,554 | 983 | ||||||
Cash and cash equivalents, beginning of year | 5,188 | 4,205 | ||||||
Cash and cash equivalents, end of year | $ | 7,742 | $ | 5,188 | ||||
Contact:
Richard L. Van Kirk, Chief Executive Officer
(949) 769-3200
SOURCE: Pro-Dex, Inc.
https://www.accesswire.com/557781/Pro-Dex-Inc-Announces-Fiscal-2019-Fourth-Quarter-And-Full-Year-Results
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Date | ticker | name | Actual EPS | EPS Surprise | Actual Rev | Rev Surprise |
|---|
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
